Stem Cell Transplant for Hematological Malignancy

Stopped early · Not applicable

Conditions studied: Leukemia, Myeloid, Chronic, AML, Leukemia, Lymphocytic, Acute, MDS, Leukemia, Lymphocytic, Chronic, JMML, Hodgkin's Disease, Non-hodgkin's Lymphoma, Multiple Myeloma

In brief

The purpose of this study is to develop a standard of care treatment using allogeneic stem cells for patients with cancers of the blood. The protocol was revised to reflect that this study is considered "treatment guidelines", rather than a research study.

Key facts

Study ID

NCT00176930

Run by

Masonic Cancer Center, University of Minnesota

People needed

330

Starts

2001-10-01

Expected to finish

2019-12-01

Last updated by the study team

2021-01-22

Who can join

Age: any, up to 55. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Donor will be <75 years of age and in good health.
• Recipients will be < or = 55 years, will have normal organ function (excluding bone marrow) and will have a Karnofsky activity assessment > or = 90%.
• Recipients with related or unrelated donor matched at the HLA A, B, DRB1 loci, or mismatched related or unrelated (if < 35 years old) at a single HLA A, B, DRB1 locus.
• Recipients will be eligible in one of the following disease categories
• Chronic myelogenous leukemia in accelerated phase or in post blast crisis second or greater chronic phase; or in chronic phase but intolerant of or resistant to tyrosine kinase inhibitors.
• Acute myelocytic leukemia in first or greater remission, or first, second or third relapse.
• Acute lymphocytic leukemia in the 2nd or greater bone marrow remission.
• High risk children will be transplanted in first remission if they meet criteria
• Myelodysplastic syndrome.
• Myeloproliferative Diseases - (i.e. myelofibrosis, chronic myelomonocytic leukemia (CMML))
• Juvenile myelomonocytic leukemia
• Chronic lymphocytic leukemia
• Advanced non-Hodgkin's (NHL).
• Advanced Hodgkin's disease beyond PR2 (> CR3, > PR3).
• Multiple Myeloma after initial therapy.
• Donors and recipients signed informed consent

You may not qualify if…

• donors and recipients should meet the following test criteria.
• required for donors:
• anti-HIV, Hepatitis B, surface antigen, anti-HCV, CMV, HSV, EBV serologies, pre-priming.
• CBC, platelet count each day of apheresis, day 0 (or 1 or 2 as needed)
• required for recipients:
• anti-HIV, Hepatitis B, surface antigen, anti-HCV, CMV, HSV, EBV serologies, pre-transplant.

Where it is running

• Masonic Cancer Center, University of Minnesota — Minneapolis, Minnesota, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.